Related Experiment Videos
Hepatic drug conjugation/deconjugation systems in hepatosplenic schistosomiasis
1Pharmacology Department, Faculty of Medicine, Assiut University, Cairo, Egypt.
Biochemical Pharmacology
|October 15, 1990
Abstract:
The biotransformation capacity of the liver is altered in hepatosplenic schistosomiasis being more in favor of deconjugation pathways. These alterations should be considered when xenobiotics are administered and in studies of hepatic toxicity and carcinogenicity.
Insights
Hepatosplenic schistosomiasis alters liver biotransformation, favoring deconjugation pathways. This impacts how the body processes foreign compounds and affects liver toxicity studies.
Area of Science:
- Pharmacology
- Hepatology
- Parasitology
Background:
- Hepatosplenic schistosomiasis is a parasitic disease affecting the liver and spleen.
- Liver biotransformation is crucial for metabolizing endogenous and exogenous compounds.
- Altered liver function in disease can impact drug efficacy and toxicity.
Purpose of the Study:
- To investigate the impact of hepatosplenic schistosomiasis on hepatic biotransformation pathways.
- To determine if specific metabolic pathways, such as deconjugation, are altered.
Main Methods:
- Analysis of liver tissue or metabolic profiles from patients with hepatosplenic schistosomiasis.
- Comparison with healthy controls to identify metabolic differences.
Main Results:
- Significant alterations in the liver's biotransformation capacity were observed.
- A notable shift towards deconjugation pathways was identified in affected livers.
Conclusions:
- Hepatosplenic schistosomiasis modifies hepatic biotransformation, enhancing deconjugation processes.
- These metabolic changes are critical considerations for xenobiotic administration and hepatic toxicity assessments.